Baudoin M, Woode ME, Nishimwe ML, et al. - In Cameroon, Côte d'Ivoire and Senegal, researchers evaluated the long‐term clinical benefits of treating chronic hepatitis C (CHC) with sofosbuvir‐based regimens. They utilized the Markov model and integrated literature data with estimates from West and Central Africa regarding direct‐acting antiviral (DAAs) efficacy. In fictive cohorts of patients “diagnosed” with CHC in Cameroon (n = 3,224), Côte d'Ivoire (n = 9,748) and Senegal (n = 6,358), the progression of the disease was simulated with and without treatment. In West and Central Africa, CHC‐related mortality could be significantly lowered with sofosbuvir-based treatment, which could also help with CHC‐related liver disease progression. Though, a substantial reduction in DAAs costs, greater political commitment and larger national and external health expenditures would be needed to eliminate this disease.